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· Favourable attitude was found among those who were trained in ECP or had read literature on ECP. A logistic regression showed that younger, trained and male providers were more likely to support ECP provision in comparison to older, untrained and female providers.
· Repeat use came up as an important issue related to OTC availability of ECP. There was confusion among KOLs and providers on what counts as repeated use. Most providers said that ECP used 2-3 times within same cycle is considered repeated use and discouraged repeated use. Sixty to 75 percent believed that ECP is being used repeatedly.
This study's findings revealed many biases and gaps in knowledge, lack of training, moral reservations and misuse. These can be used to develop programs to increase knowledge and access to ECP. An advocacy strategy including an educational campaign is needed to tackle the negative attitudes of doctors and other stakeholders.
The Government should remove the current ban on ECP advertising but provide guidelines to manufacturers for their advertisements so that careful advertisements which promote ECP to be used in emergency only can be broadcasted. In all advertisements of condoms and pills, ECP should be added as a backup support. Companies who advertise their ECP brand on TV and newspapers should also mention that it is not a regular contraceptive method.
Introduction
The Emergency Contraception Pill (ECP) is a hormone-based method providing a woman with an opportunity for preventing unwanted pregnancy after intercourse (Camp, Wilkerson & Raine, 2003; Croxatto et al., 2004;  . ECP is an important component of the range of contraceptive services in India, where unmet family planning (FP) need is about 21.3 percent (IIPS, 2010) . Several research studies across the globe have shown that ECP is safe, convenient to use, and can be effective in preventing unwanted pregnancies (WHO & JHUCCP 2011) . Findings from these research studies have encouraged several countries, including India, to make ECP available "over the counter" (OTC), without prescription.
In India, ECP was approved and introduced into the National Family Planning Program in 2002, and made an OTC drug in 2005. As an OTC drug, ECP can also be stocked and distributed by paramedics and community health workers (CHWs). Subsequently, it has been made available by government as well as non-governmental organizations along with existing contraceptives and promoted as a product that could be given in case of emergency. Data from the District Level Household and Facility Survey (IIPS, 2010) show that less than 1 percent (0.5 percent of rural and 0.8 percent of urban) of married women have ever used ECP. Furthermore, less than one-third of surveyed unmarried women knew about ECP. Awareness among currently married rural women was much lower, at 24 percent, compared to urban women at 47 percent (IIPS, 2010) . Another study during the same period (Puri et al., 2007) among female college students from Chandigarh in northern India reported only 7.3 percent of 1,017 students knowing that ECP exists. A more recent study in a medical college among a smaller sample of 300 students largely from the rural population of Uttar Pradesh (UP) showed even lower (2 percent) knowledge (Nigam, Maheshwari & Prakash, 2010) . A recent study by Population Council in rural Bihar found that 5 percent women were aware of ECP, and less than 1 percent had ever used it (Bhatnagar & Khan, 2011) .
Several individual, community and system barriers contribute to limited ECP awareness and use, including lack of accurate knowledge of its mechanism and providers' religious affiliations and fear that wide ECP availability may lead to increased sexual partners or early initiation of sex (Aksu, Basak, Yeniceri & Kaya, 2011; Rubin, Grumet & Prine, 2006; Sychareun, Phongsavan, Hansana & Phengsavanh, 2010) . Further studies have shown that providers believe easy access to ECP may lead women not only to be less likely to use other more reliable methods, but to initiate sex at a younger age, have more sexual partners, encourage sexual risk-taking, increase their risk of acquiring HIV and other STIs as well (Lawrence, Rainski, Yoon & Curlin 2010; Ehrale & Sarker, 2011; Yam et al., 2007; Blanchard, Harrison & Sello, 2005) . Moreover, Hossain-Sharif, Khan, Sebastian & Roychowdhury, 2008) providers in general tend to overestimate ECP's contraindications and side effects and do not completely support its provision without prescription (Aksu et al., 2011; Ehrle & Sarker, 2011) A study in UP has revealed that CHWs have incorrect and poor knowledge about safe methods (Goel, Bhatnagar, Khan & Hazra, 2010) .
Although limited in number, India studies show a lack of awareness among providers about correct prescribed doses of ECP and prescribed time of use (Kishore & Misro, 2010; Goel et al., 2010; Bhatnagar & Khan, 2011) . Similar to reports from other countries, providers in India also believe ECP is an essential component of contraceptive services but prefer it to be distributed only through health care providers (Tripathi, Rathore & Sachdeva, 2003; Kishore & Misro, 2010; Kumar et al., 2007) . The fear that easy ECP access will increase promiscuity and misuse is found among all providers in India (Kishore & Misro, 2010) . Another study finds that not only is ECP awareness low among CHWs such as Accredited Social Health Activists (ASHAs) (15 percent) but only 3.3 percent had ever been supplied with ECPs (Bhatnagar & Khan, 2011) .
Absence of uniform guidelines defining 'repeated use' and the number of times ECP can be used safely within the same menstrual cycle also creates hesitation about its provision among providers. Although the World Health Organization (WHO) (WHO Factsheet 244, 2005) has clearly stated that repeated ECP use does not pose any serious health risks other than minor menstrual disturbances, most providers continue to be apprehensive about repeated ECP use. These fears and hesitations are further fuelled by negative media coverage creating an imbalanced view of side-effects as well as widespread misuse, especially by unmarried young girls. For example, a recent Times of rd India article (July 23 2011, Delhi edition, Appendix), "Morning-after-pill: a medical nightmare?" portrays ECP use by young women in Delhi along with strong opinions against ECP by several well-known medical practitioners in the city. The article concludes with the warning "think twice before you pop the pill," creating ambiguity among the readers, and such media coverage may discourage greater use and engender unfavorable attitudes towards ECP, not only among potential users but among providers and policy makers as well.
The Population Council undertook this study to assess the knowledge, attitudes, and practices regarding ECP among providers in public and private facilities and pharmacies. This study's objectives are:
· Assessing providers' knowledge of ECP's biological mechanism; · Understanding providers' knowledge and attitudes about ECP's safety, effectiveness, and availability as an OTC drug;
· Identifying providers' definitions of 'repeated use' and profiling women who are 'repeated users' of ECP. This study's findings can be used to develop intervention programs and advocacy strategies increasing knowledge and access to ECP.
The quantitative survey was conducted in three of the four UP cities which were part of the Urban Health Initiative (UHI) project funded by the Bill and Melinda Gates Foundation (BMGF), as well as in Delhi, the largest city in India, with a high volume of ECP sales. The study was initially planned in the four UP UHI cities (Lucknow, Aligarh, Agra and Kanpur), but initial investigation and a consultative workshop indicated that Delhi has India's largest volume of ECP sales, and so Delhi replaced Kanpur. Subsequent surveys in the three UP cities revealed that pharmacy shops are the single most important source of ECP supply, followed by some Family Welfare Centers, and qualified doctors are consulted primarily in case of problems (e.g. menstrual issues or ECP failure), so consequently only pharmacy shops were sampled in Delhi.
Lucknow, Aligarh, and Agra are of varying sizes, with populations of diverse backgrounds and characteristics. UHI has developed an exhaustive list of public health sector facilities, maternity and nursing homes as well as a complete list of different types of providers and health workers in each city. UHI's lists served as a sampling frame for the study, but in the absence of a similar systematic listing for Delhi, a sampling frame was developed from a census of all pharmacy shops in selected areas of Delhi.
Each city was divided into four zones-east, west, north, south-and UHI's list for that city was used to locate providers in each zone. The sample was purposively selected so that providers were near or in large residential areas, urban slums, or large institutions. A total of 315 providers were selected on the criterion of ever having provided ECP services and were interviewed October and November 2011 ( Table 2) .
staff of social marketing agencies, and counselors in FP clinics attached to large public facilities. Two-thirds of providers were male and one-third female, due primarily to the fact pharmacists were principally surveyed, most pharmacists were males. Pharmacists were also, on average, seven to 10 years younger than doctors and other providers (Table 3) .
Among the 315 providers in this study, out of which 19 percent had started working before 1990, 32 percent between 1991 to 2000 and 50 percent after 2000, one-third had been trained in FP in general and only 21 percent had been specifically trained in providing ECP. A relatively larger proportion of doctors, compared to other providers or pharmacists, had been trained in ECP, and more than half were trained after 2007 (Table 4 ). Only 13 percent of providers reported receiving any brochures or other reading materials on ECP at any time, yet all of these providers reported having read the materials. The sources of these materials were mostly medical representatives, with some providers receiving them from NGOs, social marketing agencies, and the Ministry of Health and Family Welfare.
Training on ECP
Twenty nine percent providers (23 percent doctors, 52 percent paramedics and 28 percent pharmacists) expressed the need for brochures to provide information on ECP to their clients whereas 71 percent providers did not feel such need as 82 percent believed they had sufficient knowledge to provide ECP.
Almost half of providers believed that ECP prevents implantation, while 12 percent felt ECP inhibits ovulation. A large proportion reported not knowing how ECP prevents pregnancy (Table 5 ). The latest literature on ECP states that it does not prevent implantation in any way (FIGO & ICEC, 2012) , and thus this belief, largely held by doctors, needs to be addressed and corrected. Table 6 : Providers' opinions on who can use ECP (percent)*
Knowledge of ECP mechanism
Only 18 percent of providers mentioned that any woman is eligible to use ECP. Although more than half (59 percent) of providers said adolescent or unmarried women could use ECP, a large majority (80 percent) felt married women are most eligible for using ECP (Table 6 ). 55 percent of pharmacists knew it is not. Conversely, more pharmacists (20 percent) than other providers (12 percent) and qualified doctors (10 percent) believed it is an abortifacient, with one quarter of pharmacists unsure.
Women eligible for ECP When asked further on what age should be considered minimum, answers ranged from 14 to 45 years. (Table 9 ) Only approximately 14 percent of providers overall, more so among pharmacists (17 percent), felt no need for age restrictions. Further questioning on the circumstances when ECP is appropriate shows that providers accept a number of situations in which ECP could be useful and appropriate (Table 7) .
When asked whether there should be a minimum age for ECP provision, most providers (73 to 94 percent) favored minimum age restriction for ECP (Table 8) .
Over 40 percent of respondents mentioned the ages of 14 to 18 as minimum age for ECP provision, while an almost equal proportion (39 percent) recommended 19 to 24 years; around 16 percent suggested the age of 25. Disintegrated data show that the majority (32 percent) of providers believed the age of 18 should be the minimum for providing ECP; interestingly, 18 is also the minimal legal age of marriage for girls. Another one-fifth recommended 20 years as the minimum age for providing ECP. Questions about ECP's medical contraindications revealed various misconceptions and a lack of correct knowledge among providers. According to WHO's Medical Eligibility Criteria, ECP is safe in all conditions, except pregnancy (WHO, 2009). Less than 2 percent of providers stated that there are no conditions under which ECP is unsafe, and many doctors and other paramedics held misconceptions that ECP cannot be taken by women suffering from heart disease or who are breastfeeding (Table 11) . Over one third of providers, including over half of pharmacists, reported a lack of knowledge on ECP medical eligibility criteria.
Safety and effectiveness of ECP and contraindication knowledge
The vast majority of providers believed ECP is safe and effective in preventing pregnancy (Table 10 ):
*Percentages add more than100 because of multiple responses A little more than half (55 percent) of the providers agreed that women should be provided ECP as prophylactic so that it could be used when required while 26 percent opposed it (Table 12 ). However, more doctors than other providers and pharmacists did not support providing ECP on a prophylactic basis. A logistic regression analysis showed that male providers were three times more likely than female providers (OR=3.51, p<0.05) to support provision of ECP on a prophylactic basis, as were younger providers (OR =1.93, p<0.01), those who had ever received training in FP (OR=1.99, p<0.05) and those who had ever received any brochures or other educational materials on ECP (OR=2.37, p<0.05). Those who opposed the provision of ECP as prophylactic had fear that it may increase its misuse either to use it as a regular method or increase premarital sex and promiscuity. A similar probing on whether ECP could be provided OTC shows that more doctors and other trained providers than pharmacists were against provision of ECP as an OTC drug. A logistic regression analysis showed that male providers were three times more likely than female providers (OR=3.5, p<0.01) to support availability of ECP as an OTC drug. No other characteristics showed any significant difference on provision of ECP as an OTC drug, though generally less than one-third of the doctors supported provision of ECP as an OTC drug.
Most (97 percent) providers were of the opinion that ECP is easily accessible to all women who want to buy it. However a few felt that cost (9 percent), lack of awareness (5 percent) and shame or hesitation (2 percent) could pose as barriers to access for some women.
Slightly less than half (44 percent) of providers, mainly from NGOs and urban public health FP clinics, as well as pharmacists mentioned occasional stock outs, while 35 percent of all providers said they never experience any stock outs. Ninety-two percent of providers said they do not have any ECP supply problems. However, only 30 percent of providers felt all ECPs currently available in the market are of good quality, and 32 percent felt ECP's current cost is affordable.
When asked who should provide ECP, the spontaneous answers mentioned most frequently were; qualified doctors (96 percent), followed by pharmacists (63 percent). Only a quarter of providers interviewed mentioned nurses or midwives, and still a smaller percent (16 percent) mentioned CHWs or local TBAs or village doctors (5 percent) as preferred sources of ECP.
A separate direct question on whether CHW/AWW should be allowed to provide ECP, 53 percent doctors, 36 percent other providers and 19 percent pharmacists were not in favor of CHWs/AWW providing ECP because it may increase its misuse (43 percent), many do not have adequate knowledge of ECP and need prior training (34 percent) etc. In rural areas, CHWs such as ASHAs and (unqualified) village doctors could play a significant role in ensuring easy ECP accessibility to all who need it. Nevertheless, this study's findings show that more than half of doctors are still resistant to ECP provision through CHWs or other non-medical providers.
Bivariate analysis further suggests that a significantly higher proportion of male providers (74 percent) than female providers (46 percent) agree with making ECP available to all women through CHWs (z test, p<0.01).
Access, stock out and other challenges in providing ECP Preferred ECP providers
Characteristics of ECP seekers
Most providers mentioned that the majority of women seeking ECP from them are between 20 to 29 years old, with one-third of providers reporting women aged between 30 and 39 years old (Table 13 ). Ten percent of providers reported providing ECP to women under 19, primarily by pharmacists. As to be expected with these age profiles, the majority of providers reported most ECP clientele as married, while nearly half reported unmarried or student clientele. A small proportion of providers also mentioned men approaching them for ECP information or other services. Attitude towards sexual and contraceptive behavior ECP user's interviewed believed that easy access to ECP would increase the promiscuity of women and men. Still lower (66 percent) felt that it could encourage premarital sex. Fifty three percent doctors, 55 paramedics whereas a striking 74 percent pharmacists said that ECP users engage in premarital sex. Other risk behaviors mentioned by above one fourth of the providers include engagement in premarital sex and belief that easy access will increase promiscuity. About one third also felt that some couples might start using as a substitute to other regular family planning methods. (Table 14) . 
Repeated use
More than three-fourths of doctors, along with almost half of other providers and one third of pharmacists, felt ECP should not be used repeatedly in the same menstrual cycle. Large proportions of pharmacists and providers other than doctors did not know whether ECP could be used repeatedly in the same menstrual cycle (Figure 2 ).
Among the 41 providers who felt ECP could be used more than once in the same cycle, the majority recommended a limit of two times during the same menstrual cycle. About three-fourths (72 percent) of pharmacists and more than half (57 percent) of doctors believe that "many women" use ECP repeatedly. An analysis by category of providers shows that most (78 percent) doctors disapproved repeat use of ECP (i.e. use more than once in the same menstrual cycle). The corresponding figure for paramedics was 52 percent, 32 percent for pharmacists. However, those who were not sure whether ECP could be used repeatedly within the same menstrual cycle were largest among pharmacists (13 percent) followed by doctors (7 percent) and no paramedics.
Two-thirds of pharmacists (131 of 199) have provided ECP to the same woman more than once, but not necessarily in the same cycle, while only 16 percent of doctors (out of 83) and 24 percent of other providers (out of 33) reported doing so. Furthermore, over half (56 percent) of all providers said a small proportion (10 percent) of women who come to them have taken ECP before. A substantial proportion (14 percent) of the 131 pharmacists reported that more than 30 percent of women they serve have received ECP from them more than once (Table 15) . Information provided to customers requesting ECP As seen in Table 16 , 9 out of 10 pharmacists reported simply providing ECP to customers. Half of doctors said they provide general information on ECP, and were more likely than other providers and pharmacists to explain when and how to use ECP, its various side effects, and to counsel them on other FP methods
Provider suggestions for increasing ECP knowledge
Findings from key opinion leaders
Knowledge of mechanism of action Safety
A large majority (80 percent) of providers have observed a need for more media campaigns increasing public awareness of ECP. Providers recommended more advertisements on television (42 percent), mid-media campaigns, and meetings or posters (19 percent) to build ECP's image as backup support for temporary FP methods. Awareness campaigns disseminating accurate ECP knowledge through health workers and doctors were also suggested.
All 8 gynecologists knew ECP's mechanism of action, stating that ECP works by delaying or inhibiting ovulation, as is reflected in the following quote:
"The precise mechanism of how ECP works in a particular case is unknown. The action of ECP depends on time taken (after unprotected sex) and the stage of menstrual cycle. The mechanisms of action are that ECP delays ovulation, thickens the cervical mucus, directly inhibits fertilization and alters transportation of egg and the sperm." -Senior gynecologist, public hospital
Uncertainty and ambiguity about ECP's mechanism of action persists among providers; for instance, ECP's effect if taken after ovulation or implantation was unclear to many. One doctor stated:
"The exact mechanism of action is not known. But it mainly prevents ovulation and it depends what day of a menstrual cycle ECP is taken." -Senior official, Indian Medical Association
Most KOLs (8) clearly mentioned that ECP is not an abortificant. From the discussions, it seems that none of the KOLs mistook ECP as an abortificant. Six KOLs stated that ECP's effectiveness is more than 90 percent, with two stating more than 80 percent effectiveness, and one mentioning 60 to 80 percent effectiveness; the remainder mentioned that ECP is "very effective" but did not give an exact number. Six medically-trained informants, however, mentioned that ECP's effectiveness varies according to whether it is taken before or after ovulation, and how long after sex:
"The effectiveness of ECP is time bound. If you take it in the first 24 hours it is very effective and if you take it in the next 24 hours it is less effective. In general if you take it within 72 hours, I would say it is 85 percent effective." -Senior gynecologist, private hospital
Eight of 19 KOLs stated that the most common situation in which ECP could be used was contraceptive failure: Only 3 KOLs linked increasing ECP's access to promiscuity and premarital sex. For most KOLs, it was either a misconception, or they stated that premarital sex will occur with or without ECP, although 6 were unsure or did not directly disclose an opinion:
"I don't think there is any correlation between promiscuity and premarital sex. People will continue to what they want to do, but this comes as a handy tool in certain situation. ECP is what it says … it is an emergency contraceptive pill … it is for an emergency." -Senior program manager, pharmaceutical manufacturing company
Half of KOLs said increased ECP availability will not make it a substitute for regular methods, as those using a method regularly will continue and not switch to ECP, if they are satisfied with their regular method; the cost of repeated ECP use is higher, and it is less effective. Two gynecologists and 1 FP officer mentioned that most clients switch to regular methods after using ECP because of counseling, but in their experience, a few do not transition to regular methods, primarily because of misconceptions about regular methods, or because their partners do not want to use condoms or they find ECP more convenient because they have irregular sexual intercourse: Clients at large private hospitals are generally single, sexually active women, between the ages of 18 to 26 (i.e. unmarried), from the upper middle and upper class, well educated, and with infrequent sexual intercourse. Many face menstrual-related problems or have failed to protect themselves from pregnancy. Most unmarried women from lowermiddle income groups go to private clinics if they can afford the cost. Some KOLs consider ECP as a symbol of women's empowerment. A senior gynecologist stated:
"I believe it is a very safe product and it empowers the woman and it's a felt need. They only come to me when they face some problem" -Senior gynecologist, private hospital As shown in Table 17 , over one-third of KOLs could not say how many times ECP can be taken in a menstrual cycle before considered as repeated use. Almost all KOLs interviewed were concerned about repeated use. They were of the view that ECP is for emergency and should be a last effort to protect from unwanted pregnancy.
One of the biggest concerns often expressed, with as many as 13 of the 19 KOLs expressing serious concern, is that ECP is not being used as an emergency pill, nor is it advertised or promoted as such:
"If a woman is taking ECP five times it means she needs to use a regular contraceptive. The amount of progesterone taken in five times of ECP use is more than the one month's pack of OCP. The client needs to understand this; moreover, suspecting unwanted pregnancy five

Attitudes towards repeated use
Definition of repeated use:
Fear of ECP repeated use:
Number of times in a month Frequency qualifying as repeated use 
"Repeat use of ECP is a concern when we are trying to expand the use of OCPs and condoms." -Program manager, international donor agency
Gynecologists reported that women come to them either with side effects (irregular bleeding) or pregnancy, as it is easily available as an OTC drug, they may use it regularly. Gynecologists' main concern is their lack of opportunity for counseling women since ECP is an OTC drug. As a gynecologist put it:
"My only issue is that there should be a rider on ECP pack that the client should follow up with a gynecologist within 15 days of taking it, and then we can counsel women on the failure rates. What usually happens is that it is a progesterone pill and the user has a little bit of bleeding and confuses it as a normal period. But actually they have missed their period and when they come to us, they come with an advanced pregnancy." -Senior gynecologist, private hospital
Four KOLs said that if ECP is an OTC drug, public awareness about its proper use is needed. Providers should be adequately trained and ECP packaging should be properly informative or a proviso should recommend users see a gynecologist after selfadministering ECP.
Over the counter ECP provision
Could ECP help decrease abortions?
Supply, demand, and access
Barriers to women's access:
Provider challenges:
Many gynecologists (6 of 9) said it seems logical that increasing ECP's access could have led to a decline in abortions; they felt sure that the number of surgical abortion has decreased but did not have supporting statistics. As shown in Box, the key recommendations for increasing ECP access were the development of a communication plan and use of mass media for disseminating information to the public, particularly on repeated use, side effects, and emergency use only. It was also suggested that doctors, pharmacists, and CHWs providing ECP need to be adequately trained. Other suggestions for increasing access to ECP include frequent ECP updates circulated among government officials, inclusion of ECP information in all ANM and ASHA refresher courses, partnerships with rural private providers, and other forms of media including door-to-door counseling, IEC, and VHNDs for disseminating ECP information. The focus should be on adolescents and young people who can be reached through programs, sex education classes at school, the mass media and other forms of media (e.g. internet). Only one KOL said that ECP should be made available only on doctor's prescription and not as an OTC drug. Most KOLs supported ECP's continuation as an OTC drug, but some KOLs and many qualified doctors had reservations about promoting or mainstreaming ECP with other contraceptive methods; these same providers were also less supportive of its OTC status as well as its distribution by CHWs such as ASHAs. In general, doctors do not agree with ECP's de-medicalization and would prefer it to be a prescription drug, which is a matter of concern requiring advocacy to influence and change their opinions. Disseminating accurate ECP information among all provider categories could be achieved, to some extent, by including ECP in the training curricula of all doctors, nurses, and pharmacists. Periodic seminars and presentations through the official organizations of different providers such as the Indian Council of Medical Research (ICMR), Federation of Obstetrics and Gynecological Societies of India (FOGSI), or Indian Pharmacists Association could also help mitigate misconceptions about ECP and improve dispensing practices for it.
The most important rationale for ECP's introduction and funding is that it's easy access and correct use will reduce unwanted pregnancy and abortion. IDIs with doctors, however, belied their uncertainty about whether women are benefiting from ECP. Several senior gynecologists mentioned that ECP has helped reduce the rate of unwanted pregnancies and abortions, especially among young women, but they also stated this decline could be attributed to easy availability of medical abortion pills.
Some providers and KOLs felt ECP's benefits are undermined by irresponsible advertisements that result in misuse. There is a general feeling that young people are becoming more open to premarital sex, in which case ECP can prevent unwanted pregnancy, but it can be misused easily with increasing frequent use, for example half of the providers felt that easy accessibility may also lead to promiscuity. Most KOLs believe the relationship between ECP use and promiscuity is a misconception, although some do believe they are related. There is also concern that ECP may be substituted for regular contraceptive methods, but many KOLs believe it can act as a bridge to regular methods, if promoted correctly.
Manufacturers, pharmacies, and some KOLs want the Government to rescind the ban on ECP advertising but emphasize that advertisements should emphasize ECP's "emergency only" use. ECP advertisements should emphasize its emergency utilization, when another method fails, rather than as a separate method. Several experts suggested responsible advertising through mass media and promoting ECP along with other contraceptive methods would help improve its perception as a backup method among the general public and reduce misuse. Emphasizing that 'any woman in an emergency situation can use ECP' will also help reduce its stigma and the labeling of its users. As part of corporate social responsibility, medical representatives of different ECP manufacturing firms in regular contact with pharmacists could play a significant role in educating pharmacists about ECP and its overall role as an emergency device for protecting against unwanted pregnancy, and not as a regular method or abortifacient.
This report provides an analysis of the study on the knowledge, attitudes, and practices regarding the emergency contraception pill (ECP) among providers in public and private healthcare facilities and pharmacies.
The ECP is a unique method of contraception because it can be used post coital. However, its use has remained limited to urban areas, with very little penetration in rural areas. Considering the high rate of unwanted pregnancy in India, the ECP was introduced in the National The survey revealed that ECP is mainly being provided to a young section of women, by pharmacists who are not trained on ECP. Although providers believe that ECP is safe and effective, they lack correct knowledge on the mechanism of ECP and are often not in favor of easy availability of ECP to young and unmarried women. Higher availability of ECP was linked to issues such as repeated use and increase in premarital sex. The findings identify a need for educational campaigns, careful advertising, guidelines on repeat use, advocacy to tackle negative provider attitudes and IEC material which would have a direct bearing on policy, program implementation to address barriers to ECP access and to improve service delivery.
